CN-122005561-A - Application of lysine succinylation modification regulation to promotion of spermatogenesis

Abstract

The invention relates to the technical field of biological medicine, and provides an application of lysine succinylation modification regulation and control to promote spermatogenesis. Nicotinamide can alter lysine succinylation modification levels of proteins in the mouse testis and is effective in promoting spermatogenesis. The invention provides a new therapeutic scheme for clinically treating spermatogenic disorder.

Inventors

• LUO QIAN
• HUANG BEN
• ZHANG DANDAN
• PAN HONG
• SUN LONGFEI
• WANG ZHIQIANG

Assignees

• 广西壮族自治区人民医院

Dates

Publication Date

20260512

Application Date

20251230

Claims (4)

1. 1. Use of succinylation modifications in the manufacture of a medicament for promoting spermatogenesis.
2. 2. The method according to claim 1, wherein the succinylation modification is performed using nicotinamide.
3. 3. Use of modified lysine succinylation in preparing medicine for treating dysspermia is provided.
4. 4. The method according to claim 2, wherein the modification of lysine succinylation is controlled by using the lysine deacetylase inhibitor nicotinamide.

Description

Application of lysine succinylation modification regulation to promotion of spermatogenesis Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to an application of lysine succinylation modification level as a treatment for spermatogenic disorder diseases. Background The research shows that the number of sperms is reduced to different degrees in the whole world, and the number of sperms is reduced to 50-60%. In this case, the factors such as environmental pollution, bad living habit, obesity and psychological stress are further damaging to spermatogenesis, and the average fertility age is increased year by year, so that male reproductive health faces an unprecedented serious situation. The current clinical treatment scheme for male reproductive diseases mainly comprises hormone, antioxidant, traditional Chinese medicine compound and the like, however, the research considers that hormone stimulation therapy is not suitable for patients with hypergonadotropic hypogonadism and normal gonadism, and the antioxidant therapy can induce reduction stress and destroy the oxidation-reduction balance of organisms. Therefore, a treatment method which has no toxic or side effect and is universally applicable is developed, and the number and the quality of sperms are improved at the same time, thus having great significance for treating male dysspermia diseases. Disclosure of Invention The invention aims to provide an application of promoting spermatogenesis by regulating and controlling the level of lysine succinylation modification, and provides a novel treatment method for clinical spermatogenic disorder. In order to achieve the above object, the present invention provides the following technical solutions: the invention provides an application of succinylation modification in preparation of a medicament for promoting spermatogenesis. Preferably, the succinylation modification is performed using nicotinamide. The invention also provides the application of regulating and controlling the succinylation modification of lysine in preparing medicaments for treating the spermatogenic disorder diseases Preferably, the modulation of lysine succinylation modification is performed using the lysine deacetylase inhibitor nicotinamide. The invention has the beneficial effects that: The invention provides an application of succinylation modification in treating spermatogenic disorder. Nicotinamide is effective in promoting spermatogenesis and in promoting the level of succinylation modification of spermatocytes, resulting in altered succinylation modification of body testis proteins. The invention provides a new therapeutic scheme for clinically treating spermatogenic disorder. Drawings FIG. 1 testis tissue of normal control mice, scale, 100 μm. FIG. 2 cyclophosphamide modeling insemination disorder model mouse testis tissue, scale, 100 μm. FIG. 3 testis tissue, scale, 100 μm of nicotinamide dosed mice. FIG. 4 is a graph showing the results of nicotinamide promotion of succinylation modification of mouse spermatocytes. The experiment was repeated three times, different letters representing significant differences, one-way anova. FIG. 5 Wien diagrams of succinylated modified total protein (A) and differentially modified protein (B) of different treatment groups of mouse testes. FIG. 6 thermal (A) and volcanic (B) graphs of mouse testis succinylation differential modified protein (nicotinamide treated group vs. dysspermia model group). FIG. 7 GO analysis results of the mouse testis succinylation modification up-regulated (A) and down-regulated (B) proteins (nicotinamide-treated group vs. dysspermia model group). FIG. 8 results of KEGG analysis of mouse testis succinylation modifications up-regulated (A) and down-regulated (B) proteins (nicotinamide-treated group vs. dysspermia model group). Detailed Description Unless defined otherwise, technical terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which the inventive concepts pertain. The test reagents used in the following examples are all conventional biochemical reagents unless otherwise specified, and the test methods are all conventional methods unless otherwise specified. The invention will be described in detail with reference to the following examples and drawings. Example 1 1. Seminiferous disorder mouse model The invention adopts Balb/C mice, 18 male mice with age of 8 weeks are put into 21+/-1 ℃ and 55+/-5% humidity, and are fed under 12h/12h of light and shade alternate illumination conditions, so as to eat freely. After marking and adaptive feeding, the molding is started. The groups were randomized, 6 each, normal Control (NC), model Control (MC) and nicotinamide control (Nicotinamide treatment, NT), respectively. The packets are shown in table 1: TABLE 1 grouping information of mice MC and NT groups of mice were molded by intraperitoneal injecti